Template:Published case reports of bicalutamide-associated lung toxicity

Published case reports of bicalutamide-associated lung toxicity

#	Age	Sex	Dosage	Onset	Type of injury	Outcome	Ref	Link(s)
1	69 years	Male	200 mg/day	6 months	Eosinophilic lung disease	Recovered	Wong et al. (1998)
2	~76 years	Male	200 mg/day	8 months	Interstitial pneumonitis	Recovered	McCaffrey & Scher (1998)
3	~82 years	Male	80 mg/day	4 weeks	Interstitial pneumonitis	Recovered	Shioi et al. (2003)
4	~72 years	Male	80 mg/day	2.5 months	Interstitial pneumonitis	Recovered, then deatha	Shioi et al. (2005)
5	84 years	Male	?	8 months	Interstitial pneumonitis	Recovered	Kobayashi et al. (2006)
6	76 years	Male	?	?	Interstitial pneumonitis	?	Gifford & DeLong (2008)
7	85 years	Male	?	4 months	Interstitial pneumonitis	Death	Kawahara et al. (2009)
8	78 years	Male	80 mg/day	8 months	Interstitial pneumonitis	Recovered	Masago et al. (2011)
9	77 years	Male	?	7 months	Interstitial pneumonitis	Death	Song et al. (2014)
10	77 years	Male	>50 mg/day	~12 months	Interstitial pneumonitis	Death	Molina Mancero et al. (2016)
11	79 years	Male	?	1 month	Interstitial pneumonitis	Death	Polatoglu et al. (2017)
12	66 years	Male	?	?	Interstitial pneumonitis	Recovered	Kim et al. (2018)
13	66 years	Male	?	?	Interstitial pneumonitis	Recovered	Derichs et al. (2018)
14	86 years	Male	150 mg/day	6 years	Eosinophilic pneumonitis	Recovered	Umeojiako & James (2019)
15	75 years	Male	?	2 weeks	Interstitial pneumonitis	Death	Maeda et al. (2019)
16	79 years	Male	?	1.5 months	Interstitial pneumonitis	Recovered	Saito (2020)
17	66 years	Male	50 mg/day	6 months	Interstitial pneumonitis	Recovered	Smith & Antonarakis (2020)
Footnotes: a = Died of pneumothorax followed by spontaneous rupture of bulla induced by previous interstitial pneumonitis 14 months after discontinuation of bicalutamide and recovery from interstitial pneumonitis. Notes: Twelve additional cases of bicalutamide-associated interstitial pneumonitis, three of which resulted in death, were observed in an 87,000-patient cohort from MedWatch (U.S.Tooltip United States FDATooltip Food and Drug Administration passive adverse-event reporting database) between 1998 and 2000 (0.01% incidence). The median age of the patients was 73.5 years (range 59 to 91 years), and median duration of bicalutamide exposure was 7.5 weeks (range 1 to 312 weeks). Cases of interstitial pneumonitis have also been reported in association with flutamide, nilutamide, and gonadotropin-releasing hormone (GnRH) agonists.

Template documentation

See also

• Side effects of bicalutamide § Lung toxicity

References

Editors can experiment in this template's sandbox (create | mirror) and testcases (create) pages.
Subpages of this template.